<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361956</url>
  </required_header>
  <id_info>
    <org_study_id>CR108410</org_study_id>
    <secondary_id>2017-001110-29</secondary_id>
    <secondary_id>56136379HPB2001</secondary_id>
    <nct_id>NCT03361956</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection</brief_title>
  <official_title>A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in
      terms of changes in hepatitis B surface antigen (HBsAg) levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main study consists of 2-parts and each part will consist of 2 types of Chronic Hepatitis
      B-infected participant populations. Each part of the study will consist of screening phase
      (up to 8 weeks), treatment phase (24 weeks or 48 weeks, depending on treatment response), and
      post-treatment follow-up phase (24 weeks or 48 weeks, depending on treatment response). The
      duration of individual participation will be up to approximately 56 weeks (participants not
      eligible to continue treatment in extension phase), up to 80 weeks (participants continuing
      treatment in extension phase but not meeting treatment completion criteria), or up to 104
      weeks (participants meeting treatment completion criteria). The safety and efficacy will be
      monitored throughout the study. In a separate substudy, at selected clinical sites,
      percutaneous core liver biopsy will be performed to evaluate changes of intrahepatic viral
      parameters.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">February 8, 2021</completion_date>
  <primary_completion_date type="Actual">September 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main Study: Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in Hepatitis B surface antigen (HBsAg) levels at Week 24 will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main Study: Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to Follow Up (maximum up to Week 96)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Follow Up (maximum up to Week 96)</time_frame>
    <description>A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Number of Participants with Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram (ECG), Clinically Significant Laboratory Findings</measure>
    <time_frame>Up to Follow Up (maximum up to Week 96)</time_frame>
    <description>Number of participants with abnormalities in vital signs, physical examinations, ECG, clinically significant laboratory findings will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Change from Baseline in Hepatitis B Surface Antigen (HBsAg) Levels</measure>
    <time_frame>Baseline up to follow up (maximum up to Week 96)</time_frame>
    <description>Change from baseline in Hepatitis B surface antigen (HBsAg) levels will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With HBsAg Levels Less Than (&lt;) 1,000 or &lt;100 IU/mL</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Percentage of participants with HBsAg levels less than (&lt;) 1,000 or &lt;100 International Units Per Milliliter (IU/mL) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With Greater Than (&gt;) 0.5 or &gt;1 log10 IU/mL Reduction in HBsAg From Baseline</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Percentage of participants with &gt;0.5 or &gt;1 log10 IU/mL reduction in HBsAg from baseline will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic acid (DNA) Levels</measure>
    <time_frame>Baseline up to follow up (maximum up to Week 96)</time_frame>
    <description>Change from baseline in Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With Undetectable HBV DNA Levels</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Percentage of participants with undetectable HBV DNA levels will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Change From Baseline in Hepatitis B E Antigen (HBeAg) Levels</measure>
    <time_frame>Baseline up to follow up (maximum up to Week 96)</time_frame>
    <description>Change from baseline in Hepatitis B E antigen (HBeAg) levels will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants by HBeAg Levels</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Percentage of participants by HBeAg levels will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With HBsAg or HBeAg Seroclearance</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Percentage of participants with seroclearance (defined as HBsAg or HBeAg negativity, respectively) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With HBsAg or HBeAg Seroconversion</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Percentage of participants with seroconversion (defined as HBsAg or HBeAg negativity and anti-HBs or anti-HBe antibody positivity, respectively) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With Normalized Alanine Aminotransferase (ALT) Levels</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Percentage of participants with normalized alanine aminotransferase (ALT) levels will be assessed whose ALT levers above upper limit of normal at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With Virological Breakthrough</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Percentage of participants with viral breakthrough defined as confirmed on treatment HBV DNA increase by greater than (&gt;) 1 log10 from nadir level or confirmed on treatment level &gt;200 International Units Per Milliliter (IU/mL) in participants who had HBV DNA level below the lower limit of quantification (LLOQ) of the HBV DNA assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Plasma Concentrations of NA (Entecavir [ETV] or Tenofovir Disoproxil Fumarate [TDF])</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26 and 28</time_frame>
    <description>Plasma concentrations of NA (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]) administered as monotherapy or co-administered with JNJ-56136379, will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Plasma Concentrations of JnJ-56136379</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 26 and 28</time_frame>
    <description>Plasma concentrations of JNJ-56136379 administered as monotherapy or when co-administered with NA (ETV or TDF), will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Percentage of Participants With Treatment-Associated Mutations</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 26, 28, 36 and 48</time_frame>
    <description>Viral genome sequence analysis will be performed to evaluate emergence of mutations associated with JNJ-56136379 and/or ETV or TDF treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Substudy: Change from Baseline in Intrahepatic Hepatitis B Virus (HBV) Covalently Closed Circular Deoxyribo Nucleic Acid (cccDNA) Levels at Week 24 and 48</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>Change from baseline in intrahepatic HBV cccDNA levels at Week 24 and 48 will be assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Substudy: Change from Baseline in HBV cccDNA Transcriptional Activity at Week 24 and 48</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>Change from baseline in HBV cccDNA transcriptional activity at Week 24 and 48 will be assessed. cccDNA and intracellular viral RNA levels will be used to estimate transcriptional activity of cccDNA.</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Part A: Arm 1 (JNJ-56136379 or NA) (open label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]), and enter the 24 week post treatment follow-up phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Arm 2 (Placebo+NA [ETV] or [TDF])</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Arm 4 (Placebo + NA [ETV or TDF])</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Arm 7 (placebo + NA [ETV or TDF])</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Arm 9 (placebo + NA [ETV or TDF])</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-56136379</intervention_name>
    <description>Participants will receive JNJ-56136379 tablet orally.</description>
    <arm_group_label>Part A: Arm 1 (JNJ-56136379 or NA) (open label)</arm_group_label>
    <arm_group_label>Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)</arm_group_label>
    <arm_group_label>Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <other_name>JNJ-6379</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo tablet orally.</description>
    <arm_group_label>Part A: Arm 2 (Placebo+NA [ETV] or [TDF])</arm_group_label>
    <arm_group_label>Part A: Arm 4 (Placebo + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 7 (placebo + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 9 (placebo + NA [ETV or TDF])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NA (ETV or TDF)</intervention_name>
    <description>Participants will receive NA (ETV or TDF) tablet orally as per approved label.</description>
    <arm_group_label>Part A: Arm 1 (JNJ-56136379 or NA) (open label)</arm_group_label>
    <arm_group_label>Part A: Arm 2 (Placebo+NA [ETV] or [TDF])</arm_group_label>
    <arm_group_label>Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part A: Arm 4 (Placebo + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)</arm_group_label>
    <arm_group_label>Part B: Arm 7 (placebo + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])</arm_group_label>
    <arm_group_label>Part B: Arm 9 (placebo + NA [ETV or TDF])</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a body mass index (weight in kilogram (kg) divided by the
             square of height in meters) of 18.0 to 35.0 kilogram / square meter (kg/m^2), extremes
             included

          -  Participants must have chronic hepatitis B virus infection (CHB) infection documented
             by: Serum hepatitis B surface antigen (HBsAg)-positive at screening and serum HBsAg-
             or hepatitis B virus (HBV) deoxyribonucleic acid (DNA)-positive at least 6 months
             prior to screening; Serum immunoglobulin M (IgM) anti- hepatitis B core-related (HBc)
             antibody negative at screening

          -  In participants currently not being treated (Treatment Arms 1-2-3 and 6-7-8):
             Participants must not be receiving any CHB treatment at screening, that is, Have never
             received treatment with HBV antiviral medicines, including NAs or interferon (IFN)
             products, OR Have not been on treatment with HBV antiviral medicines, including
             nucleos(t)ide analog (NA)s or IFN products within 6 months prior to baseline (first
             intake of study drugs), and participants must be HBeAg-positive and have HBV DNA
             greater than or equal to (&gt;=) 20,000 International Units Per Milliliter (IU/mL), OR be
             hepatitis B e antigen (HBeAg)-negative and have HBV DNA &gt;=2,000 IU /mL at screening,
             and participants must have HBsAg greater than (&gt;) 250 IU/mL at screening, and
             participants must have alanine aminotransferase (ALT) &gt; upper limit of normal (ULN)
             and less than or equal to (&lt;=) 5 * ULN at screening, determined in the central
             laboratory

          -  In virologically suppressed participants (Treatment Arms 4-5 and 9-10): Participants
             must be virologically suppressed by current NA treatment (entecavir (ETV) or tenofovir
             disoproxil fumarate (TDF)) as defined by HBV DNA less than (&lt;) 60 IU/mL at screening
             and at least 6 months prior to screening, and participants must be on the same NA
             treatment (ETV or TDF) and the same dose for &gt;=12 months prior to screening, and
             participants must have HBsAg &gt; 250 IU/mL at screening, and participants must have ALT
             &lt;=2*ULN at screening

          -  Participants must have: A liver biopsy result classified as Metavir F0-F2 within 1
             year prior to screening or at the time of screening, OR FibroScan liver stiffness
             measurement &lt;8.0 kilopascal (kPa) within 6 months prior to screening or at the time of
             screening

        Exclusion Criteria:

        Main Study:

          -  Participants who test positive for anti-hepatitis B surface (HBs) antibodies

          -  Participants with current hepatitis A virus infection (confirmed by hepatitis A
             antibody immunoglobulin M [IgM]), hepatitis D virus (HDV) infection (confirmed by HDV
             antibody), hepatitis E virus infection (confirmed by hepatitis E antibody IgM), or
             human immunodeficiency virus (HIV)-1 or HIV-2 infection (confirmed by antibodies) at
             screening; participants with a history of or current HCV infection (confirmed by HCV
             antibody). Evidence of other active infection (bacterial, viral, fungal, including
             acute tuberculosis) deemed clinically relevant by the investigator that would
             interfere with study conduct or its interpretation will also lead to exclusion

          -  Participants with any evidence of hepatic decompensation at any time point prior to or
             at the time of screening: Direct bilirubin &gt;1.2* ULN, or International normalized
             ratio (INR) &gt;1.5* ULN, or Serum albumin &lt; lower limit of normal (LLN), or documented
             history or current evidence of variceal bleeding, ascites, or hepatic encephalopathy

          -  Participants with a history of cardiac arrhythmia (example, extrasystoli, tachycardia
             at rest), history of risk factors for Torsades de Pointes syndrome (example,
             hypokalemia, family history of long QT syndrome) or history or other clinical evidence
             of significant or unstable cardiac disease (example, angina, congestive heart failure,
             myocardial infarction, diastolic dysfunction, significant arrhythmia, coronary heart
             disease, and/or clinically significant 12 lead electrocardiograms (ECGs)
             abnormalities), moderate to severe valvular disease, or uncontrolled hypertension at
             screening

          -  Participants with contraindications to the use of ETV or TDF per local prescribing
             information

        Substudy:

          -  Presence of coagulopathy or hemoglobinopathy (including sickle cell disease,
             thalassemia)

          -  Use of any anti-coagulant, anti-platelet, or non-steroidal anti-inflammatory drug
             medications from 10 days before until 5 days after each liver biopsy

          -  Presence of ascites, focal liver lesions, and other findings that would be
             contraindications for liver biopsies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Office of Franco Felizarta, MD</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center (TMC)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.D. Care, Inc.</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Hepatology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Center For Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Institute (G.I.R.I.)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>ON M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beiijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Johann Wolfgang Goethe- Universität Frankfurt Medizinische Klinik 1</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg, Haus Lifi - Studien und Projekte GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale Maggiore Di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashino Red Cross Hospital</name>
      <address>
        <city>Musashino</city>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Nagasaki Medical Center</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Bahiyah</name>
      <address>
        <city>Alor Setar</city>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Chorzowie</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony</name>
      <address>
        <city>Kielce</city>
        <zip>25-317</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wroclawskie Centrum Zdrowia</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-136</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center 'SibNovoMed' LLC</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Company 'Hepatolog' Ltd</name>
      <address>
        <city>Samara</city>
        <zip>443063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol State Medical University</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Linkou Branch</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10500</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Of Songkla University</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saglık Bilimleri University Şişli Trainig and Research Hospital,Department of Gastroenterology</name>
      <address>
        <city>İstanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical of Faculty, Department of Gastroenterology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv National Medical University, Regional Clinical Infectious Hospital</name>
      <address>
        <city>Kharkiv</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE 'National institute therapy named L.T. Maloi NAMS of Ukraine'</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Clinical Hospital</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia City Clinical Hospital #1, Department of Infectious Diseases #1</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Crumpsall</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grahame Hayton Unit</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

